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Abstract
Background: Transcutaneous tibial nerve stimulation (TTNS) and percutaneous tibial nerve stimulation (PTNS) are
effective and safe therapies for overactive bladder (OAB) syndrome in adults. However, few randomized sham-
controlled trials have been conducted in a pediatric population. To our knowledge, both therapies never have been
compared in children.
Aim: The aim of the complete study is twofold: (1) to assess the efficacy of TTNS therapy on bladder symptoms
after 12 weeks of treatment in a pediatric population with idiopathic overactive bladder syndrome (iOAB) and/or
nocturnal enuresis (part I) and (2) to assess the effect of TTNS compared to PTNS (part II). In this article, we aim to
present the protocol of the first part of the TaPaS trial (TTNS, PTNS, sham therapy).
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Methods: Part I of the TaPaS trial is set up as a single-center randomized-controlled trial. Children, aged from 5 to
12 years with iOAB and/or nocturnal enuresis, are assigned to two groups by computer-generated randomization:
TTNS therapy (intervention) and sham therapy (control). The primary outcome is the percentage difference in
average voided volume (AVV) between baseline and after 12 weeks of treatment. Secondary endpoints are the
percentage difference in supervoid volumes, number of urinary incontinence episodes/24 h and in voiding
frequency, the difference in parent reported outcomes between baseline and after 12 weeks of treatment, and the
duration of clinical response.
Discussion: We hypothesize that TTNS is a non-inferior treatment for iOAB in children compared to PTNS therapy.
Since literature is inconclusive about the efficacy of TTNS in a pediatric population, a sham-controlled RCT on TTNS
will be conducted (part I). A protocol for a prospective randomized sham-controlled trial has been developed.
Enrolment has started in November 2018. Study completion of part I is expected by August 2021.
Trial registration: ClinicalTrials.gov NCT 04256876. Retrospectively registered on February 5, 2020.
Keywords: Urinary bladder, Overactive bladder, Nocturnal enuresis, Children, Transcutaneous electric nerve
stimulation, Randomized controlled trial
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Introduction
Background and rationale {6a}
The reported prevalence of daytime lower urinary tract
dysfunctions (LUTD) in children ranges widely from 1
to 20% [1]. Among these, overactive bladder syndrome
(OAB) as a storage dysfunction and dysfunctional
voiding as an emptying dysfunction are the two main
entities. Failure to achieve continence (normally reached
by the age of three to four), urgency, frequency,
hesitancy, and frequent urinary tract infections (UTIs)
are reported complaints. Nocturnal enuresis, without
daytime LUTD, is considered as a separate entity and
has an estimated prevalence of 5–10% at the age of
seven [1].
In the management of both OAB and nocturnal
enuresis, the objective is to increase the bladder capacity
if reduced for the age. Conservative therapy like lifestyle
advice and behavioral modifications, including bladder
re-education and bowel management, is the first step in
a multimodal approach (urotherapy). In case conserva-
tive therapy fails, anticholinergic drugs are the mainstay
of medical treatment. As an alternative, in case one is re-
luctant towards pharmacotherapy or in case pharmaco-
therapy has failed, peripheral neuromodulation can be
offered.
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Different types of peripheral neuromodulation have
been practiced in the pediatric population like
transcutaneous electrical nerve stimulation (TENS)—on
the sacrum or over the posterior tibial nerve (TTNS)
and percutaneous tibial nerve stimulation (PTNS) [2, 3].
However, to our knowledge, no exact data on how
frequently adopted this treatments are, are published.
In our department, PTNS is the alternative treatment
for OAB in case there are contra-indications for the use
of drug therapy or in case a non-drug therapy is pre-
ferred. It is proven to be effective and safe in children
with iOAB [4]. However, the time-consuming weekly in-
office visits and the percutaneous approach make ther-
apy child-unfriendly. The transcutaneous technique, by
contrast, is non-invasive and can be easily applied at
home. It would benefit the patient and the parents if
TTNS would form an equal alternative to PTNS therapy.
Besides few reactions such as skin reactions from the ad-
hesive electrodes, no serious adverse events have been
reported in TENS therapy [3, 5].
Ramírez-García et al. conducted a prospective efficacy
study on TTNS compared to PTNS therapy as treatments
for adults with OAB. The authors could demonstrate the
non-inferiority of TTNS in comparison to PTNS in de-
creasing daytime voiding frequency [6]. However, the
non-inferiority of the transcutaneous technique over the
percutaneous technique in a pediatric population has not
been proven so far.
In the TaPaS trial—acronym for Transcutaneous tibial
nerve stimulation, Percutaneous and Sham therapy—we will
evaluate both the superiority of TTNS over sham therapy
(part I) and the non-inferiority of TTNS compared to PTNS
in children with idiopathic OAB (iOAB) (part II).
To our knowledge, only two sham-controlled RCTs
have been published on the efficacy of TTNS in children
with OAB. In the first study published by Boudaoud
et al., 20 children with OAB were randomized into a
TTNS and a sham group. The clinical results remained
the same between both groups, underlining the potential
placebo effect of any type of management in this popula-
tion [7]. In the second study by Patidar et al. a signifi-
cant benefit of TTNS over sham therapy in a study
population of 40 children with OAB was seen [8]. Since
the results of both trials are contradictive, we decided to
set up a new similar RCT in order to be able to conduct
part II.
Objectives {7}
The objective of part I of the TaPaS trial is to evaluate
the superiority of TTNS therapy over sham therapy. It is
set-up as a small clinical trial in order to obtain own
data, enabling us to conduct part II. The end objective
of the TaPaS trial is to show the non-inferiority of TTNS
over PTNS therapy.
Trial design {8}
A prospective, single-center randomized controlled
double-blinded trial is set up, comparing TTNS versus
sham therapy. Participants are allocated on a 1:1 ratio to
either the intervention arm, either or the control arm,
according to a computer-generated list of random num-
bers. Superiority of TTNS over sham will be assessed.
Methods: participants, interventions, and
outcomes
Study setting {9}
The recruitment of participants is carried out by pediatric
urologists and pediatric nephrologists from the Department
of Urology and at the Department of Pediatrics at the
academic hospital of the Ghent University (East-Flanders,
Belgium). Children attending a pediatric specialist (PS) for
urgency incontinence or bedwetting are eligible for inclusion.
The inclusion criteria are listed below.
At the initial visit, the child with lower urinary tract
symptoms (LUTS) is subjected to a complete diagnostic
work-up according to the standard of care [9]. Besides a
baseline history-taking assessment, a few additional eval-
uations are performed: urine sample analysis, a bladder
and kidneys ultrasound (US), and an uroflowmetry with
an US guided post-void residual (PVR) measurement. A
3 days daytime bladder diary and a 7 nights night-time
bladder diary are distributed [10]. Based on the com-
pleted bladder diaries and the baseline work-up, children
are diagnosed at the second visit and subsequently
screened for eligibility.
Eligibility criteria {10}
Patients who meet the following criteria are eligible for
inclusion:
 Diurnal urgency urinary incontinence and/or
nocturnal enuresis (primary or secondary).
 Aged from 5 to 12 years old.
 Being treatment–naïve or only having been treated
with urotherapy (see the “Intervention description
{11a}” section for a detailed definition of
urotherapy).
 Having a parent or guardian who is able to complete
bladder diaries reliably.
Exclusion criteria are the following:
 Patients already treated with non-conservative ther-
apies, i.e., any drugs with anticholinergic effect,
transcutaneous electrical nerve stimulation (TENS),
PTNS, or intradetrusor botulinum toxin injections.
 Patients with a neurogenic bladder dysfunction.
Ghijselings et al. Trials          (2021) 22:247 Page 3 of 13
 Patients with dysfunctional voiding, diagnosed by
the presence of a staccato-shaped curve on uroflow-
metry at the moment of screening.
 Patients with nocturnal polyuria, registered on a 7
days night-time bladder diary. Nocturnal polyuria is
defined by the International Children’s Continence
Society (ICSS) as a nocturnal urine production ex-
ceeding 130% of the expected bladder capacity for
age [10].
 Patients with behavior disorders like attention-deficit
hyperactivity disorder.
 Patients with learning disabilities and/or lack of
capacity, unable to comprehend urotherapy”
Who will take informed consent? {26a}
If a child is eligible for inclusion, the child and parent(s) or
guardian are verbally informed about the study by their PS
and a written patient information sheet is distributed. If both
parties are willing to participate, an informed consent for the
parent and an informed consent adapted to minors (from 8
to 12 years old) are signed by the respective parties.
Subsequently, an appointment for a first visit at the pediatric
physiotherapist is made. A research assistant, also being a
medical doctor, can function as an authorized surrogate to
take informed consent.
Both the participant and investigator receive a signed
copy of the consent form. Paper IC forms are stored and
kept confidential in the archives of the data management
unit. At all times, the IC form can be requested by the
institutional data protection officer.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
There are no additional informed consents needed since
no biological specimens are taken.
Interventions
Explanation for the choice of comparators {6b}
The results of the two only RCTs that have been
conducted to compare TTNS and sham therapy in
children are conflicting [7, 8]. Therefore, we chose to set
up a new sham-controlled RCT.
Intervention description {11a}
Intervention group
Active neuromodulation treatment is delivered by the
Transcutaneous Electrical Nerve Stimulation (TENS)
device from BioMedical Life Systems, the Impulse 3000
T®. The physiotherapist places a round self-adhesive sur-
face electrode (Ø3.2 cm) on the tibia, 2 cm superior
from the medial malleolus (the negative electrode). The
positive electrode is placed in the middle of the medial
foot arch on the conduct of the posterior tibial nerve
(see Fig. 1). Stimulation parameters are set on a fixed
pulse width of 200 μS and a pulse frequency of 20 Hz. In
literature, no consensus is reached on the ideal stimula-
tion settings of TTNS [11]. Most studies report a pulse
width of 200 μs [3]. We decided to choose the same fre-
quency (20 Hz) as the previous study by Patidar et al.
since significant results in this active treatment arm were
seen [8].
During the therapy session, parents are instructed by
the physiotherapist how to apply the surface electrodes
themselves. By increasing the pulse intensity by turning
the wheel, the TENS device will be switched on. The
pulse intensity (in volt) is increased till a comfortable,
painless sensation is felt. While increasing the pulse
intensity, no motor responses may occur. During the
following 30 min, in-office stimulation is given.
At the end of the session, the same device is given to
the parents in order to apply ambulant therapy (AT).
Parents are instructed to apply the TENS-device on the
ankle of their child 1 h daily during the next 12 weeks
(two times 6 weeks with 1 visit at the physiotherapist in
between), without changing the fixed settings. The
TENS device must always be placed on the same ankle.
If habituation to the electrical impulse occurs, the pulse
intensity should be set around the perception threshold.
The intensity may be increased from 1 to 20 V, but
stimulation may never be considered as painful. To con-
ceal the allocation of treatment (effective treatment ver-
sus sham) for parents and child, they are told they
cannot determine by sensation to which study group
they belong. Parents who had previous experience with
Fig. 1 Application of the TENS device
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TENS devices are told they cannot compare this TENS
therapy with their own since stimulation settings are
each time different for every indication.
Sham group
The same TENS device, electrode positioning, pulse
frequency (20 Hz) and pulse width (200 μs) as in the
intervention group are applied for the sham group.
Unlike the intervention arm, the pulse intensity
button is set on position number “1,” which is the
test button on which no electric current is delivered.
Parent and child are told that subsensory stimulation
will be delivered, not affecting the outcome as
proven earlier in other types of neuromodulation
trials [12]. In this way, we counter their worry that
no sensation is felt. To discourage children or
parents from exceeding number 1, they are told
higher stimulations can affect the result of treatment
in a negative way.
The same stimulation protocol as for the intervention
group (1 h daily during 2 periods of 6 weeks) needs to be
followed at home after the first visit. When switching
the TENS-device on, they may not exceed number 1.
This way, no current is supplied.
To check whether this method of blinding was
successful, at the end of the trial, both parent and child
are asked to indicate to which group they think they
belonged.
Urotherapy
Besides neuromodulation, every participant in the trial
will receive the same standard Urotherapy. Urotherapy
can be defined as a bladder re-education or rehabilita-
tion program aiming for the correction of filling and
voiding difficulties [13]. It encompasses the following
components [10]:
 Education on normal lower urinary tract (LUT)
functioning and on how the LUT function of the
child differs from normal.
 Lifestyle advices: counseling on drinking (1,5 L–2 L
fluid intake daily) and voiding habits, diet, reduction
of caffeine intake, proper stool management, etc.
 Behavioral modifications: sustaining regular voiding
habits and adequate toilet positioning, avoiding
holding maneuvers, etc.
 Regular follow-up and encouragement strategies:
specifically for this trial, a follow-up visit at the
physiotherapist will occur after 6 (the second visit)
and 12 weeks (the third visit) of AT.
 Registration of symptoms, drinking, voiding, and
stool habits through diaries.
Specifically for this trial, a 1-day bladder diary must be
completed consistently every week as part of the
urotherapy. Additionally, 3 times weekly, the participant
must try to hold up urine for 5 min if the urge to urinate
comes up. Gradually, the duration of delayed urinating
should be trained to be increased. The so-called super-
voids are part of urotherapy.
In the sixth week, a 7 day night-time bladder diary
must be completed. After the second visit at the physio-
therapist, the participant must continue the stimulation
and urotherapy (plus completion of the diaries and
supervoids) for another 6 weeks.
After the third visit, an observation period of 6 weeks
is carried out during which no stimulation is given.
Urotherapy however should be continued.
Study schedule
For a structured overview of the study schedule, see Fig. 2
and Table 1. After enrolment, the participant is referred
to the physiotherapist for a first visit (t1). Urotherapy and
a first neuromodulation session are given. After home-
therapy for 6 weeks, a second evaluation visit at the
physiotherapist is planned (t2). Together with the parent
and participant, the progression in symptoms is evaluated
by review of the completed diaries. After the second 6-
week period of home-therapy, a third follow-up visit at
the physiotherapist is planned (t3). Primary outcomes are
collected and delivered to the research assistant. At this
point (at 12 weeks), the degree of clinical response to the
treatment will be assessed. “No response” is defined as less
than 50% increase in the average voided volume (AVV)
compared to baseline, registered in the bladder diary.
“Partial response” is predefined as 50–99% increase in the
AVV, and “Complete response” as a 100% increase in
AVV [10].
To evaluate the duration of clinical response, a third
period of 6 weeks without any treatment (the observation
period) is inserted. During this “wash-out” period, the
same set of bladder diaries must be completed.
The study is closed at the end of the last follow-up
visit at 18 weeks at the treating PS (t4). The PS will be
briefed beforehand to which treatment arm the partici-
pant was allocated. The same assessment as during base-
line will be repeated and the parent and participant will
be unblinded during this follow-up visit.
For post-trial care, see item 30.
Criteria for discontinuing or modifying allocated
interventions {11b}
In case a dermal allergic reaction from the self-adhesive
electrodes as an expected adverse event would occur,
hypoallergenic electrodes will be provided to the partici-
pants, free of charge. On the participant’ request, the
therapy can be discontinued at any time in the course of
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Fig. 2 CONSORT flowchart of the TaPaS trial part I
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Table 1 Schedule of enrolment, interventions and assessments
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the study. No reason for this request should be given. In
case symptoms would improve or worsen during ther-
apy, no modifications to the stimulation protocol are
allowed.
Strategies to improve adherence to interventions {11c}
At the first study visit, extensive counseling of the
importance of therapy compliance is given to the parents.
Adherence to therapy will be stimulated by the required
completion of bladder diaries and the active encouragement
of the participant and parent by the physiotherapist during
the 6-weekly follow-up visits. During the follow-up visits, the
potential progression of symptoms will be actively evaluated
by going through the completed diaries, together with the
participant.
To check the adherence to the treatment protocol by
the participant, registration of the performance and
duration of daily TENS-application in a diary will be
requested.
Relevant concomitant care permitted or prohibited
during the trial {11d}
During the trial, the following bladder medication may
not be taken: Anticholinergic drugs and a β3 receptor
agonist (i.e., mirabegron). Medication to stimulate bowel
movement and treat constipation (such as laxative) are
permitted. Another form of neuromodulation like sacral
TENS is prohibited.
Provisions for post-trial care {30}
The study is closed at 18 weeks. Participants who had
received partial or complete clinical success at 12 weeks
(independently from the allocated group) can either
choose to stop any further treatment or receive further
therapy along the standard of care (i.e., bed-wetting
alarm if enuresis is still present, pharmacotherapy or
percutaneous tibial nerve stimulation (PTNS)).
If participants belonged to the sham group and did
not perceived clinical success, voluntary enrolment in
part II of the TaPaS trial is possible, wherein TTNS will
be compared to PTNS therapy. No financial support for
post-trial care will be provided.
Outcomes {12}
All outcomes will be assessed after 12 weeks of
treatment and will be compared to baseline measures.
Outcomes will be reported both as:
– Median (IQR) absolute change from baseline −
median (IQR) percentage change from baseline.
Primary outcome
* To show that TTNS therapy is superior to sham
therapy in terms of average voided volume (AVV).
 The endpoint is the median change in baseline at 12
weeks in AVV, registered on the daytime bladder
diary. The AVV is calculated by the sum of all voids
during daytime (in ml) of 3 days in total divided by
the frequency of voids during daytime over 3 days in
total. We consider AVV as the most relevant
variable to measure efficacy since it directly reflects
the functional bladder capacity. Increasing the
functional bladder capacity is the key of in OAB
and/or nocturnal enuresis (in the absence of
nocturnal polyuria) treatment. An increased bladder
capacity should ultimately lead to a decrease in
micturition frequency and in urinary incontinence
episodes. The follow-up interval of 12 weeks was
chosen since the effect of treatment can be expected
after 12 weeks of treatment.
Secondary outcomes
The mean volume of supervoids This is the median
change in the mean volume of three “supervoids”
between week 12 and week 1, registered on the 3 days
daytime bladder diary. See the “Interventions” section
for the definition of supervoids. Same as for the primary
outcome, this outcome reflects the change in bladder
capacity.
Number of urgency incontinence episodes during
daytime and night-time This is the median change of
urinary incontinence episodes compared to baseline
registered in a 3 days daytime bladder diary and night-
time bladder diary (the average of 7 nights).
For parents and participants, this is the most relevant
clinical outcome since it significantly affects daily
activities mostly.
Mean voiding frequency during daytime This is the
median change in diurnal voiding frequency registered
in the 3 days daytime bladder diary.
Parents reported satisfaction of urinary symptoms
Parents are asked to rate the following question: ‘How
would you feel as a parent or guardian if your child’s
bladder symptoms were to remain as they are on at this
moment?” A score on a Likert-scale from 1 (extremely
dissatisfied) to 7 (extremely satisfied) at baseline and
after 12 weeks of treatment must be given.
The parent or guardian is the most trustworthy source
to obtain a subjective assessment. Therefore, a parent
reported instead of patient reported outcome is
obtained.
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Duration of effect The duration of persistent partial or
complete response during the observation period of 6
weeks, expressed in weeks. Same as during the
treatment period, one diurnal bladder diary must be
completed every week. This tells us more about the
maintenance of clinical effect that is either received by
active stimulation plus urotherapy or by urotherapy
alone and a potential placebo effect.
Participant timeline {13}
For a participant timeline see Fig. 3.
For a schedule of enrolment, interventions, and
assessment, see Table 1.
Sample size {14}
For the sample size calculation, an online software
package was used:
Sealed Envelope Ltd. 2012. Power calculator for
continuous outcome superiority trial. [Online] Available
from: https : / /www.sea ledenvelope .com/power/
continuous-superiority.
The trial has a parallel superiority design. Based on the
previous study by Patidar et al. [8], a mean difference of
20% in the primary outcome (i.e., percentage difference in
AVV between baseline and after 12 weeks) between TTNS
and sham can be expected, with an estimated standard
deviation of 20. A sample size of 24 participants (12 in
each treatment arm) is then required to achieve a power
of 80% for two-sided testing at a 5% significance level.
Recruitment {15}
To reach an adequate sample size, recruitment of
participants is performed by different pediatric specialists
from both the Urology and Pediatric Nephrology
Department during the consultations. We chose to
include patients who have not been treated yet with non-
conservative therapies, among others to increase the num-
ber of potential participants. Additionally, treatment-naïve
patients are easier to convince to participate in a sham-
controlled trial than patients who have been unsuccess-
fully treated and want the guarantee of an effective
treatment.
Assignment of interventions: allocation
Sequence generation {16a}
The randomization sequence list was computer-generated
using the online platform “Sealed envelope” (available at:
sealedenveloppe.com). Randomization is generated with a
parallel 1:1 allocation of two treatment groups A and B,
using random block sizes of 4. No stratification of partici-
pant characteristics was implemented.
Independently from the randomization sequence list,
the physiotherapist defined randomly groups A and B
(TTNS or sham).
Subsequently, the randomization sequence list was
exempted for use to the physiotherapist.
Concealment mechanism {16b}
The allocation sequence is not concealed for the
physiotherapist, who assigns and implements the
interventions. From the moment a participant is sent for a
first visit to the physiotherapist, she allocates a number to
the participant in order of appearance. The sequentially
numbered participants will receive the treatment as
indicated in the order of the randomization sequence list.
The research assistant, however, who analyzes all the
data, is neither aware of the participant number, the
group allocation per participant, nor of the identification
of group A and B.
Fig. 3 Participant timeline TaPaS trial
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Implementation {16c}
Participants will be enrolled by the PS or the research
assistant. Afterwards, the allocation sequence is generated by
coincidence. The participant schedules an appointment with
the physiotherapist according to his or hers own preference
in time and the availability of the physiotherapist. This
sequence will determine the sequentially numbered list who
is developed by the physiotherapist. Assignment of
participants to interventions is also performed by the latter.
Assignment of interventions: blinding
Who will be blinded {17a}
The treatment is blinded for the patient, the parent, the
treating PS, and the research assistant. The physiotherapist is
the only unblinded party.
Procedure for unblinding if needed {17b}
In case the participant and parent want to discontinue
with the trial, the allocated intervention will be revealed.
In no other circumstances, unblinding is allowed. The
treating PS will be unblinded before the last follow-up
visit at 18 weeks. The research assistant will be un-
blinded after all data has been entered into the database.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Bladder diaries and the parents reported satisfaction of
urinary symptoms questionnaire are distributed at the
beginning of treatment on paper. The demographic data
from each participant will be derived from the electronic
medical record (EMR). All outcome data will be
collected at the end of the 12 weeks treatment period
and converted by the research assistant into a digital file.
A standard frequency-volume chart with additional in-
formation of urinary incontinence episodes and urgency
episodes will be used as bladder diary [10]. The parents’
reported satisfaction of urinary symptoms score is a
non-validated 7 points Likert scale.
The following case report forms will be collected (see
also Fig. 3 and Table 1):
-t1: First visit with the PS.
CRF with baseline patient characteristics: age, gender,
presence of daytime urinary incontinence and/or
enuresis nocturna, and comorbidities.
CRF with technical investigations: presence of urinary
tract infection (yes/no), kidney ultrasound (US) (normal
or abnormal), PVR on bladder US (ml), cystometric
bladder capacity at uroflowmetry, and staccato pattern
on uroflow suggestive for dysfunctional voiding (Y/N).
0: Second visit with the PS.
CRF with baseline daytime and nighttime diary
parameters (volume intake, daytime diuresis, micturition
frequency, AVV during the day, urgency episode (Y/N),
number of urinary incontinence episodes, N of
defecations, N of wet nights, nocturnal urine production,
netto urine loss/night, presence of nocturnal polyuria),
and parents’ reported satisfaction of urinary symptoms.
t1: First visit with the PT.
CRF with patient number, allocation group.
t2: Second visit with the PT, 6 weeks after ambulant
treatment.
CRF with daytime and nighttime diary parameters
after 6 weeks of treatment (same parameters as at visit
2 + averaged volume of 3 supervoids at 6 weeks) and
parents reported satisfaction of urinary symptoms.
CRF with recorded (serious) adverse effects: the
adverse event form.
*t3: Third and last visit with the PT, 12 weeks after
ambulant therapy.
Same CRF’s as in t2.
CRF with treatment response (non-responder, partial
responder, complete responder).
*t4: Third visit with the PT.
Same CRF’s as in t2.
CRF with the maintenance of treatment effect in
partial and complete responders (in weeks).
Plans to promote participant retention and complete
follow-up {18b}
The short duration of the clinical trial (i.e., 18 weeks)
should be the most important incentive to complete the
whole trajectory. By inserting a follow-up visit in the
middle of the study period, participants are promoted to
continue the treatment protocol. Participants who dis-
continue treatment are no longer candidates to be in-
cluded in part II of the TaPaS trial.
Data management {19}
Data is entered manually in on an online firewall
protected data registry on the password-encrypted server
of the Ghent University. Subsequently, data will be
stored in a central IBM SPSS database which is also pro-
tected by the institutional firewall. Only the trial coord-
inator has access to both data registries. To promote
data quality, data will be controlled on impossible values
by range checks.
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Confidentiality {27}
The participants’ data are pseudo-anonymized by assign-
ing an unique code to every participant at the moment
of inclusion to ensure confidentiality. Data will be stored
during and after the trial in an online protected data
registry and IBM SPPS database, only accessible by the
trial coordinator and at the end of the study by the CI.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
No laboratory examinations are performed; biological
specimens are not to be collected.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Statistical analyses will be performed using SPSS version
25.0. Descriptive statistics of demographic characteristics
will be presented by median and interquartile ranges
(IQR) for continuous variables and frequencies and
percentages for categorical variables. Since the small
sample size, non-parametric tests will be chosen. In case
a subject withdraws early, a new participant will replace
them till the required sample size is reached. An ITT
will be performed. If case data are missing, missing data
will be imputed via multiple imputation.
° Intra-arm analyses (baseline vs. 12 weeks):
Baseline and 12 weeks follow-up absolute values and
absolute change and percentage change from baseline
values will be presented as medians (IQR). Intra-arm
analyses will be assessed using a two-sided Wilcoxon
signed rank test.
° Inter-arm analyses (sham versus TTNS therapy): dif-
ferences in absolute and percentage change from base-
line between both groups will be reported as medians
(IQR) and will be presented with a 95% confidence
interval.
Inter-arm analyses will be assessed using a two-sided
the Mann-Whitney U test
Interim analyses {21b}
No interim-analysis will be carried out.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
No subgroup analyses will be carried out.
Changes in fluid intake between baseline and after
treatment will be statistically examined by a Wilcoxon
signed rank test. In case a significant difference is noted,
logistic regression analysis can be performed to examine
whether change in fluid intake is an independent
predictor for partial response or complete response to
treatment or sham (> 50% increase in AVV at 12months
follow-up).
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
The non-adherence to the treatment protocol by the
participant can be detected by controlling the diaries
that report the daily duration of application of TENS-
therapy. We are counting therefore on the participant’s
reliability and honesty. In case non-adherence is noticed,
besides the aforementioned intention-to-treat analysis,
an additional per-protocol analysis will be carried out.
A missing value analysis will be performed. If data is
missing (completely) at random, a multiple imputation
model will be used, followed by a sensitivity analysis.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
Participant data may be available upon request (lynn.
ghijselings@ugent.be) after completion of the trial.
Oversight and monitoring
Composition of the coordinating center {5d}
The coordinating center is the Ghent University
Hospital as an ERN eUROGEN accredited center. The
trial management group is composed as follows:
– The CI: Prof. Dr. Anne-Françoise Spinoit.
– The trial coordinator: Dr. Lynn Ghijselings, i.e., the
research assistant.
– The physiotherapist: Ms. Catherine Renson.
– Co-investigators: Dr. Lynn Ghijselings, Ms.
Catherine Renson—an institutional biostatistician.
– An institutional data protection officer will protect
every process of data management and will verify if
every step in this process is according to current
privacy regulations.
– The trial is monitored by the HIRUZ Clinical Trial
Unit HIRUZ (Ghent University Hospital’s ‘Health,
Innovation and Research’ department) Data
Management Unit (DMU). They perform on-site
and remote monitoring according to the Inter-
national Council for Harmonization of Technical
Requirements for Pharmaceuticals for Human Use –
Good Clinical Practice (ICH-GCP) guidelines.
Since the small sample size of the trial, the decision
was made not to have a trial steering committee.
Composition of the data monitoring committee, its role
and reporting structure {21a}
Since previous trials have been conducted with TTNS in
children showing no serious adverse events [5], there is
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no formal appointed independent data monitoring
committee. Any potential harm or risk to the patients
will be assessed by a section of the HIRUZ clinical trial
unit. This section has no conflict of interests in the trial
or medical device company. In case of any risk to the
patient’s safety, the chief investigator, sponsor of the
trial and ethical board will be informed. Dependent from
the severity of the AE, the decision to prematurely stop
the clinical trial will be taken.
Adverse event reporting and harms {22}
During each follow-up visit, the physiotherapist will
query the participant for adverse events. In case adverse
events occur during ambulant therapy, participants are
asked to contact the physiotherapist. This information
will be briefed to the CI, who will include all the details
(time of occurrence, severity and attribution of the
event—related or non-related to the therapy) on the ad-
verse events form. AE will be quarterly reported to the
Ethical Board or the Ghent University.
Adverse events will be treated along the standard of care.
Serious adverse events (SAE), also reported on the
Adverse Event form, will be immediately (within 24 h)
reported by the CI to the sponsor, the Ethical Board,
and the FAGG (Federal Agency of Medicines and Health
products). In case of any unexpected SEA of SUDA
(serious adverse device effect), the study will be stopped.
However, there are no SEA to be expected from TTNS,
as previous studies in adults have proven its safety [3].
Frequency and plans for auditing trial conduct {23}
An internal audit will be planned by the institutional
clinical trial unit HIRUZ (clinical trials unit of Ghent
University Hospital’s “Health, Innovation and Research”
department.) This organization has no conflict of
interests.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
In case important changes will be needed to be
undertaken, an amendment on the original protocol will
be communicated to the Institutional Review Board
(IRB) and the co-investigators.
Dissemination plans {31a}
In case the superiority of TTNS over sham therapy is
proven, phase II of the TaPaS trial will be launched. Since
showing the non-inferiority of TTNS compared to PTNS
is the ultimate objective of the TaPaS trial, only results of
part II will be communicated to a broader public. Trial re-
sults of part I will be submitted in the form of an original
article for peer review in a not yet determined journal.
Discussion
We do not expect there to be major practical or
operational difficulties in the implementation of the trial.
The biggest issue lies within the limited control on the
adherence to treatment. Since the treatment is mainly
home-based, there is little control on how strictly partic-
ipants will have applied the TENS device daily. The re-
quirement to complete regular bladder diaries and
register the applied home–therapy does not guarantee
full trial compliance and so compliance bias cannot be
avoided.
Trial status
The treatment protocol version 2 was approved by the
Ethical Board of the Ghent University Hospital on 6
November 2018 (B670201837682). Recruitment has
started in November 2018 and is still pending. Due to
the COVID-19 pandemic, recruitment has been delayed.
The expected study completion of recruitment of part I
(TTNS vs. Sham) will be postponed to December 2021.
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